GSK plc reported on October 8, 2024, that their RSV vaccine, Arexvy, demonstrated cumulative efficacy of 62.9% against lower respiratory tract disease over three seasons in older adults, indicating significant health benefits. The study involved 25,000 participants and highlighted the vaccine's safety and effectiveness, particularly for those at increased risk.